MIMETIS BIOMATERIALS SL

Their core work

Mimetis Biomaterials is a Barcelona-based biotech SME that designs and manufactures 3D-printed bone substitute materials engineered to mimic the architecture of natural bone. Their core product is patient-specific synthetic bone scaffolds produced via additive manufacturing, targeting surgical applications in cranio-maxillofacial, dental, and orthopedic reconstruction. In EU-funded research, they have contributed both as a technical partner — supplying biomaterial expertise for randomized clinical trials — and as a project coordinator leading the development of next-generation biomimetic grafts. Their work sits at the intersection of computational design, materials science, and clinical validation, translating laboratory-grade biomimicry into implantable medical devices.

What they specialise in

How they've shifted over time

Mimetis entered H2020 through MAXIBONE (2018) as a research participant in a clinically-oriented RIA project, contributing 3D-printed biomaterials to a controlled trial for maxillofacial reconstruction — the emphasis was on validating the technology against biological benchmarks like autologous stem cells. By 2019 they had taken the coordinator seat in Bone3Dmatch under the SME-2 scheme, signalling a deliberate move from research contributor to commercial product developer: the keyword set broadened from specific clinical contexts to platform-level terms like regenerative medicine, additive manufacturing, patient specific, and scaffolds. The trajectory is a textbook SME maturation arc — validate in a research consortium, then lead your own commercial development project with a larger budget (€795,840 vs €320,596).

Mimetis is moving from research validation into product-led development, and their coordinator experience in Bone3Dmatch suggests they are positioning to anchor future consortia rather than join them as a supplier.

How they like to work

Mimetis has demonstrated both roles in EU projects — joining as a technical partner (MAXIBONE) and leading as coordinator (Bone3Dmatch) — which is unusual and valuable for a two-project SME. Their network of 13 partners across 6 countries in just two projects suggests active consortium building rather than passive participation. The step up to coordinator on their larger-budget project indicates they are capable of managing multi-partner consortia and have the administrative infrastructure to do so.

Mimetis has built a network of 13 unique partners across 6 countries through only two projects, suggesting deliberate partner diversification rather than repeat collaboration. Their geographic spread is European, with Spain as the hub.

What sets them apart

Mimetis occupies a narrow but high-value niche: they are not a generic biomaterials supplier, but a company specifically focused on patient-specific, 3D-printed scaffolds that replicate natural bone microarchitecture. This biomimicry-first approach differentiates them from standard synthetic graft manufacturers and from academic labs that lack production capability. For consortium builders in regenerative medicine or medical device development, they offer the rare combination of material science expertise, additive manufacturing capability, and clinical trial experience within a single SME.

Highlights from their portfolio

• Bone3Dmatch
  Mimetis coordinated this SME-2 project (€795,840) — their largest funding to date — focused on patient-specific biomimetic bone materials, representing their pivot from research partner to commercial product leader.
• MAXIBONE
  This RIA project paired 3D-printed biomaterials from Mimetis with autologous mesenchymal stem cells in a randomized clinical trial, providing rare clinical-grade validation evidence for their scaffolds.